Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

The agency seeks more clinical data on canakinumab in refractory patients after an advisory committee meeting that focused on the drug's potential risks.
Advertisement

Related Content

Novartis Stockpiling Priority Review Vouchers
Novartis Stockpiling Priority Review Vouchers
Ilaris Complete Response Letter Raises Questions About The Validity of Priority Review Vouchers
Priority Review Voucher Value Still Confounds, But Remains An Incentive For Sponsors
Juvenile Arthritis Data For Novartis' Ilaris Also Supports Role In Gouty Arthritis
Ilaris Gout Review Reflects Tougher FDA Approach To Biologic Dosing Safety
Novartis Gambles Priority Review Voucher On Ilaris Gout Indication
Ilaris Safety Data Inadequate For Gout Indication, FDA Panel Says
Ilaris Safety Data Inadequate For Gout Indication, FDA Panel Says
Novartis Ilaris Approved For Rare Autoinflammatory Disorder; Filings For More Common Diseases Planned

Topics

Advertisement
UsernamePublicRestriction

Register

PS072702

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel